A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Differentiated Thyroid Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 26, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 187 (final count)
- Started
- Oct 5, 2018
- Main results expected
- Aug 19, 2020
- Fully finished
- Jul 31, 2027
- Results posted
- May 18, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.
Objective Response Rate (ORR)
Measured over: Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03690388 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC